Table 3. Clinical and Laboratory Features with Respect to Outcomes in Patients with VITT.*.
| Variable | Patients Who Were Alive (N=170) |
Patients Who Died (N=49) |
|---|---|---|
| Age — yr (range) | 48 (40–55) | 47 (32–56) |
| Sex — no./total no. (%) | ||
| Male | 79/97 (81) | 18/97 (19) |
| Female | 90/120 (75) | 30/120 (25) |
| Median days since vaccination (IQR) | 14 (11–17) | 13 (10–16) |
| Cerebral venous sinus thrombosis — no./total no. (%) | ||
| No | 100/117 (85) | 17/117 (15) |
| Yes | 70/102 (69) | 32/102 (31) |
| Intracranial hemorrhage — no./total no. (%) | ||
| No | 145/172 (84) | 27/172 (16) |
| Yes | 25/47 (53) | 22/47 (47) |
| Platelet count <30,000 per mm3 — no./total no. (%) | ||
| No | 135/161 (84) | 26/161 (16) |
| Yes | 33/56 (59) | 23/56 (41) |
| Median platelet count (IQR) — per mm3 | 52,000 (34,000–80,000) | 30,000 (16,000–57,000) |
| Median fibrinogen level (IQR) — g/liter | 2.3 (1.5–3.2) | 1.7 (1.1–2.9) |
| Median d-dimer level (IQR) — FEU | 20,000 (7,000–36,000) | 28,000 (13,000–57,000) |
| PF4 — no./total no. (%) | ||
| Negative | 5/6 (83) | 1/6 (17) |
| Positive | 159/198 (80) | 38/198 (19) |
| Not performed | 6/16 (38) | 10/16 (62) |
*
Shown are the numbers of patients in each category for whom data were known. Data on age and the platelet count were available for 217 patients (167 who were alive, 49 who had died, and 1 with an unknown outcome), data on days since vaccination were available for 218 patients (168 who were alive, 49 who had died, and 1 with an unknown outcome), and data on the fibrinogen and d-dimer levels were available for 202 patients (160 who were alive, 41 who had died, and 1 with an unknown outcome).